Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye scanner showdown: do two machines see glaucoma the same way?

NCT ID NCT07350304

Diagnosis Sponsor: Twin Cities Eye Consultants Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested how well two different eye imaging machines (Topcon Maestro2 and Zeiss Cirrus 5000) agree when measuring retinal thickness in people with glaucoma. Researchers scanned 141 eyes from patients with mild to severe glaucoma using both devices. The goal was to see if doctors can trust measurements from either machine and to create formulas to convert results between them, helping ensure consistent care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help eye doctors use different OCT machines interchangeably, making glaucoma monitoring more consistent across clinics.
What could go wrong
This is a completed observational study, not a treatment trial. The results only show how well the devices agree; they do not improve glaucoma outcomes directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

141 people

The number who actually took part.

Started

Oct 2024

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consisted of adult patients aged 18 years or older with established or suspected glaucoma. Subjects were consecutively enrolled from a single tertiary ophthalmology practice in Minnesota. The final cohort included a range of glaucoma severity (mild, moderate, and severe) and was predominantly composed of White (59.6%) and female (59.6%) individuals. All participants underwent same-day, back-to-back OCT imaging on both the Topcon Maestro2 and Zeiss Cirrus 5000 systems.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female patients at least 18 years of age * A diagnosis of mild, moderate or severe glaucoma. * Optic nerve appearance characteristic of glaucoma. * \< +/- 6D Spherical equivalent Refractive Error * BCVA ≥ 20/40 * Previous Zeiss OCT RNFL with signal strength of ≥ 7/10 * The subject is able to understand the requirements of the study and provide written informed consent. * Subject is willing to follow study instructions, agrees to comply with all study procedures and testing. Exclusion Criteria: * If pseudophakic, PCO must be ≤ trace * If phakic, the cataract must be ≤ 1+ * No diagnosis of optic nerve disease other than glaucoma, and no macular disease. * Current participation or participation in any drug or device clinical trial (which includes the fellow eye) within the past 30 calendar days.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glaucoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glaucoma

Contacts and locations

Locations

  • Twin Cities Eye Consultants

    Coon Rapids, Minnesota, 55433, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.